WO2012138147A3 - Forme cristalline de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique et son procédé de préparation - Google Patents
Forme cristalline de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique et son procédé de préparation Download PDFInfo
- Publication number
- WO2012138147A3 WO2012138147A3 PCT/KR2012/002575 KR2012002575W WO2012138147A3 WO 2012138147 A3 WO2012138147 A3 WO 2012138147A3 KR 2012002575 W KR2012002575 W KR 2012002575W WO 2012138147 A3 WO2012138147 A3 WO 2012138147A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystalline form
- indol
- pyrazole
- cyano
- isopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne une forme cristalline du composé de formule (1) et son procédé de préparation.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014503602A JP6008937B2 (ja) | 2011-04-06 | 2012-04-05 | 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 |
CN201280016696.6A CN103459381B (zh) | 2011-04-06 | 2012-04-05 | 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0031490 | 2011-04-06 | ||
KR20110031490 | 2011-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012138147A2 WO2012138147A2 (fr) | 2012-10-11 |
WO2012138147A3 true WO2012138147A3 (fr) | 2012-11-29 |
Family
ID=46969691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/002575 WO2012138147A2 (fr) | 2011-04-06 | 2012-04-05 | Forme cristalline de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique et son procédé de préparation |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6008937B2 (fr) |
KR (1) | KR101424013B1 (fr) |
CN (1) | CN103459381B (fr) |
TW (1) | TWI548630B (fr) |
WO (1) | WO2012138147A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
CN106045898B (zh) * | 2016-06-28 | 2019-05-24 | 广东东阳光药业有限公司 | 一种吲哚类化合物及其制备方法和用途 |
WO2018097294A1 (fr) * | 2016-11-28 | 2018-05-31 | 帝人ファーマ株式会社 | Médicament thérapeutique ou médicament prophylactique pour une néphropathie diabétique |
TW202336015A (zh) | 2020-11-04 | 2023-09-16 | 南韓商Lg化學股份有限公司 | 唑-4-羧酸結晶之製備方法及包含彼之醫藥組成物 |
AR124178A1 (es) | 2020-12-01 | 2023-02-22 | Lg Chemical Ltd | Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación |
AU2021392532A1 (en) | 2020-12-01 | 2023-06-29 | Lg Chem, Ltd. | Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same |
TW202245755A (zh) | 2021-04-16 | 2022-12-01 | 南韓商Lg化學股份有限公司 | 包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸之口服用複合調配物 |
CN117255785A (zh) * | 2021-04-27 | 2023-12-19 | 株式会社Lg化学 | 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法 |
AU2022270242A1 (en) * | 2021-04-29 | 2023-12-21 | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. | Class of xanthine oxidase inhibitors |
KR20220168173A (ko) | 2021-06-15 | 2022-12-22 | 주식회사 엘지화학 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물 |
AR126164A1 (es) | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
WO2023208103A1 (fr) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | Composé pouvant être utilisé pour la goutte |
WO2023208108A1 (fr) * | 2022-04-27 | 2023-11-02 | 江苏新元素医药科技有限公司 | Composé pour réduire l'acide urique |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027186A1 (fr) * | 1996-01-25 | 1997-07-31 | MERCK Patent Gesellschaft mit beschränkter Haftung | 1-(pyrazol-3-yl-ethyl)-4-(indol-3-yl)-piperidine utilisee comme medicaments agissant sur le systeme nerveux central |
WO2007113647A1 (fr) * | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Formes polymorphes de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-méthyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazépino[4,5,6-cd]indol-8-yl)acétamide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0810524B8 (pt) * | 2007-04-11 | 2021-05-25 | Kissei Pharmaceutical | derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado |
WO2008126901A1 (fr) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant |
TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
-
2012
- 2012-03-30 TW TW101111308A patent/TWI548630B/zh active
- 2012-04-05 JP JP2014503602A patent/JP6008937B2/ja active Active
- 2012-04-05 CN CN201280016696.6A patent/CN103459381B/zh active Active
- 2012-04-05 KR KR1020120035349A patent/KR101424013B1/ko active IP Right Grant
- 2012-04-05 WO PCT/KR2012/002575 patent/WO2012138147A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027186A1 (fr) * | 1996-01-25 | 1997-07-31 | MERCK Patent Gesellschaft mit beschränkter Haftung | 1-(pyrazol-3-yl-ethyl)-4-(indol-3-yl)-piperidine utilisee comme medicaments agissant sur le systeme nerveux central |
WO2007113647A1 (fr) * | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Formes polymorphes de (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-méthyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazépino[4,5,6-cd]indol-8-yl)acétamide |
Also Published As
Publication number | Publication date |
---|---|
CN103459381B (zh) | 2015-12-09 |
WO2012138147A2 (fr) | 2012-10-11 |
KR101424013B1 (ko) | 2014-08-18 |
JP2014510133A (ja) | 2014-04-24 |
JP6008937B2 (ja) | 2016-10-19 |
TW201245182A (en) | 2012-11-16 |
TWI548630B (zh) | 2016-09-11 |
CN103459381A (zh) | 2013-12-18 |
KR20120114174A (ko) | 2012-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012138147A3 (fr) | Forme cristalline de l'acide 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylique et son procédé de préparation | |
JOP20210065A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
WO2012103279A3 (fr) | Procédés et compositions pour la synthèse d'agents de multimérisation | |
PH12015501226A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same | |
MY150280A (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
MX360062B (es) | Metodos de elaboracion de fenilacetato de l-ornitina. | |
HUE052128T2 (hu) | Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására | |
PH12015500160A1 (en) | Method of producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazole-3-yl]pyridin-2-carbonitrile, and intermediary thereof | |
WO2011015287A3 (fr) | Procédé pour la préparation de dérivés d'acide 1-(2-halogénobiphényl-4-yl)-cyclopropanecarboxylique | |
WO2012030106A3 (fr) | Procédé de production d'un composé intermédiaire pour la synthèse d'un médicament | |
WO2012140490A3 (fr) | Procédé de préparation de dérivé de quinoléine | |
WO2011102640A3 (fr) | Procédé de préparation de sitagliptine et sels d'amines intermédiaires utilisés dans ce procédé | |
WO2014087208A3 (fr) | Procédé de préparation d'alcaftadine | |
MX2012001722A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
WO2012044043A3 (fr) | Nouveau procédé de préparation de dérivés de benzoimidazole | |
WO2010089267A3 (fr) | Procédé de production de dérivés d'acide 2-halogénométhylphénylacétique | |
WO2013072938A3 (fr) | Procédé amélioré pour la préparation de roflumilast | |
WO2012134103A3 (fr) | Dérivé à base d'ester de norbornène, son procédé de fabrication et ses utilisations | |
GB2523674A (en) | Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof | |
EP2687515A4 (fr) | Procédé pour produire un dérivé d'acide pyrazolecarboxylique | |
WO2009122429A3 (fr) | Oxybutynine cristalline et son procédé de préparation | |
MX2012000877A (es) | Nuevas alcoxienonas y enaminocetonas y un procedimiento para su preparacion. | |
WO2012050623A3 (fr) | Nouveaux composants d'acide phénoxyisobutyrique et procédés de synthèse | |
BR112012010486A2 (pt) | processo para preparação de compostos 1-3 pirazol, processo para preparação de um acido pirazolcarboxilico da formula ia e processo para preparação de um composto da formula v | |
WO2013078446A3 (fr) | Dérivés d'acide phénoxyisobutyrique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12767405 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014503602 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12767405 Country of ref document: EP Kind code of ref document: A2 |